Show simple item record

dc.contributor.authorZwart LL de
dc.contributor.authorHaenen HEMG
dc.contributor.authorVersantvoort CHM
dc.contributor.authorSips AJAM
dc.date.accessioned2007-02-26T16:13:23Z
dc.date.available2007-02-26T16:13:23Z
dc.date.issued2002-06-28en_US
dc.identifier623860011en_US
dc.identifier.urihttp://hdl.handle.net/10029/9261
dc.description.abstractBoth in the development of medicinal products as well as in risk assessment of other xenobiotics there is an increasing awareness that children should be considered as a special group. Children are exposed to other doses than adults and the pharmacokinetics and pharmacodynamics can be very different in children and adults. In general it can be concluded that the effects of age on pharmacokinetics are most pronounced during the first 6-12 months of life. Full adjustment of dosing or TDI's for pharmacokinetic differences can relatively easily be applied and should, to our opinion be seen as a first step in considering risk for the paediatric population. For risk assessment for drugs as well as for other xenobiotics, it seems to be essential that young animal models will be used for determining NOAELs, that are relevant for the paediatric population. The use of a paediatric PBPK model possibly combined with pharmacodynamics (PBPK/PD model) may be a valuable aid in risk assessment.
dc.format.extent1411000 bytesen_US
dc.format.extent1444416 bytes
dc.format.mimetypeapplication/pdf
dc.language.isoenen_US
dc.publisherRijksinstituut voor Volksgezondheid en Milieu RIVMen_US
dc.relation.ispartofseriesRIVM rapport 623860011en_US
dc.relation.urlhttp://www.rivm.nl/bibliotheek/rapporten/623860011.htmlen_US
dc.subject.otherrisk assessmenten
dc.subject.otherpharmacokineticsen
dc.subject.otherchildrenen
dc.titlePharmacokinetics of ingested xenobiotics in children: A comparison with adultsen_US
dc.title.alternativeFarmacokinetiek van orale xenobiotica in kinderen: Een vergelijking met volwassenenen_US
dc.contributor.departmentLBVen_US
refterms.dateFOA2018-12-18T16:46:34Z
html.description.abstractBoth in the development of medicinal products as well as in risk assessment of other xenobiotics there is an increasing awareness that children should be considered as a special group. Children are exposed to other doses than adults and the pharmacokinetics and pharmacodynamics can be very different in children and adults. In general it can be concluded that the effects of age on pharmacokinetics are most pronounced during the first 6-12 months of life. Full adjustment of dosing or TDI's for pharmacokinetic differences can relatively easily be applied and should, to our opinion be seen as a first step in considering risk for the paediatric population. For risk assessment for drugs as well as for other xenobiotics, it seems to be essential that young animal models will be used for determining NOAELs, that are relevant for the paediatric population. The use of a paediatric PBPK model possibly combined with pharmacodynamics (PBPK/PD model) may be a valuable aid in risk assessment.


Files in this item

Thumbnail
Name:
623860011.pdf
Size:
1.377Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record